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Active Surveillance and Isolation of Asymptomatic Carriers of 
Clostridium difficile at Hospital Admission:
Containing What Lies Under the Waterline
Alice Y. Guh, MD, MPH and L. Clifford McDonald, MD
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, 
Georgia.
During the 2000s, the incidence of Clostridium difficile infection (CDI) increased 
dramatically, in large part due to the emergence of a hypervirulent strain, BI/NAP1/027, 
responsible for many hospital outbreaks in the United States. In 2011, C difficile accounted 
for 12% of all US health care–associated infections, surpassing Staphylococcus aureus as the 
most common cause of such infections.1 Hospitalized patients with CDI are a recognized 
source of health care–associated (HA) transmission, and a primary control measure is to 
limit the spread of the organism from symptomatic patients. However, increasing molecular 
evidence, based on genomic sequence–based methods, indicates that asymptomatic patients 
colonized with C difficile also contribute to transmission.2,3 A 2013 study3 found that 
incident CDI cases in a hospital were as frequently linked to transmission from 
asymptomatic carriers as to symptomatic patients. Despite the potential for patients with 
asymptomatic colonization to serve as a reservoir for CDI, no data currently exist to 
determine whether interventions targeting asymptomatically colonized patients could be 
effective in reducing HA-CDI.
In this issue of JAMA Internal Medicine, Longtin et al4 report findings from a quasi-
experimental controlled study using time series analysis to determine the effect of active 
surveil-lance and isolation of asymptomatic carriers on the incidence of HA-CDI. The 
authors conducted rectal sampling of all patients admitted through the emergency 
department of a tertiary acute care hospital over an approximate 17-month period. 
Clostridium difficile testing was performed using a polymerase chain reaction (PCR) assay 
that targeted the tcdB gene and has been demonstrated to detect the subset of carriers with 
heavier organism loads who were more likely to contaminate the skin or environment.5 All 
identified asymptomatic carriers were placed under isolation precautions until discharge. 
Among 7599 of 8218 patients screened, 4.8% were identified as asymptomatic carriers, 
which is similar to a previous study6 that included additional Québec hospitals. However, 
other researchers have reported a higher prevalence of carriage on admission, ranging from 
7% to 18%.7 Longtin et al4 did not provide the proportion of all patients admitted who were 
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either transferred from other hospitals or directly admitted from long-term care facilities. 
Although these individuals are likely to be higher-risk patients, they were excluded from 
screening due to logistical restraints, and their exclusion could have contributed to the low 
prevalence of asymptomatic carriage. The limited sensitivity of direct screening using a 
commercial PCR (ie, insufficient for detecting carriers with lower organism burden) might 
be another reason for the lower prevalence.
Nonetheless, Longtin et al4 found that the incidence of HA-CDI decreased by 7% per 4-
week period during the intervention period, resulting in an overall decrease of 7.2 cases per 
10 000 patient-days. The intervention was estimated to have prevented 63 of 101 expected 
cases. This meant that, for every single HA-CDI case prevented, 121 patients had to be 
screened, and 6 asymptomatic carriers had to be isolated. No concomitant decrease in the 
incidence of HA-CDI was detected among other hospitals in Québec City and throughout 
Québec province. It is conceivable that more cases would have been prevented if periodic 
screening was performed among patients after admission, identifying additional carriers who 
were missed during admission screening. In addition, a greater reduction of HA-CDI 
incidence might have been detected if it had not been for the previously mentioned 
limitations (ie, exclusion of direct admissions and transfers and use of a less sensitive 
screening method).
Several strengths of this study should be noted. Although the study design was not as 
rigorous as a cluster randomized approach, multiple statistical methods were used to 
measure the effect of the intervention, including segmented regression analysis and 
autoregressive integrated moving average modeling, and these analyses produced similar 
results, while accounting for seasonality and changes in diagnostic as-says. Multiple control 
hospitals were also included for inter-hospital comparison. Other important confounders that 
were assessed included hand hygiene compliance and antibiotic and proton pump inhibitor 
use. Hand hygiene compliance increased during the intervention phase, but almost all hand 
hygiene was performed with an alcohol-based hand sanitizer, which is not effective against 
C difficile spores.
The results of this study are promising for reducing HA-CDI. Additional information on 
patient-specific factors that could have affected the incidence of HA-CDI, such as whether 
asymptomatic carriers were less likely than noncarriers to receive antibiotics and therefore to 
develop CDI, would be helpful. Adherence to isolation precautions was also not assessed to 
ensure that the intervention was adequately implemented. In addition, isolation precautions 
were modified to allow asymptomatic carriers to share a room with noncarriers as long as 
the curtain separating the 2 beds was drawn. The effectiveness of this approach in preventing 
C difficile transmission is unknown, and no data were available regarding the proportion of 
noncarrier roommates who subsequently developed CDI. Furthermore, environmental 
cleaning was not as sessed to determine if there were improvements during the in tervention 
phase that could have affected HA-CDI rates.
The feasibility of implementing active surveillance for C difficile needs to be carefully 
considered. At present, there is no standardized method for detecting asymptomatic carriage 
of toxigenic C difficile. Limited data suggest that rectal culture might be as sensitive as stool 
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culture for detecting asymptomatic carriage among hospitalized patients. Perirectal sampling 
has been shown to be an accurate and efficient method for detecting toxigenic C difficile in 
symptomatic patients, but its effectiveness in asymptomatic carriers has not been widely 
studied. Moreover, none of the commercially available nucleic acid amplifications tests (eg, 
PCR) for diagnosing CDI have been approved by the US Food and Drug Administration for 
detection of asymptomatic carriers.
Practical challenges and disadvantages to implementing active surveillance and isolation 
precautions also exist. Screening all patients who are admitted can be labor and resource 
intensive, particularly given the cost of PCR assays, although Longtin et al4 estimated that 
the intervention might have been cost-effective. Private rooms might not be readily available, 
and isolation of all detected carriers would contribute to the shortage of rooms. In addition, 
isolation has been shown to negatively affect patients’ quality of life and can cause anxiety 
and depression, particularly in patients on long-term isolation.8 Using a modified approach 
to isolation precau tions, as was done in the study by Longtin et al,4 might mitigate some of 
the negative psychological effect, although the effectiveness of this strategy requires further 
evaluation. Other options to explore that could be potentially cost-effective and allow for a 
judicious use of resources include targeting active surveillance to patients at high risk for 
asymptomatic carriage, particularly those at high risk of spore shedding (eg, history of prior 
CDI with recent antibiotic use) or those admitted to high-risk wards (eg, intensive care 
units).
The severity of disease and complications associated with CDI can result in tremendous 
distress among patients and substantial increases in cost. Preventing transmission of C 
difficile is critical to limiting its serious effects, which might be more effectively achieved by 
targeting asymptomatic carriers in addition to symptomatic patients with CDI. Longtin et al4 
have shown the possible benefit of using active surveillance testing and isolation of 
asymptomatic carriers for preventing HA-CDI. Larger, well-designed studies, such as cluster 
randomized trials, are ultimately needed to confirm the effectiveness of this strategy. Similar 
investigations need to be conducted in long-term care settings, where there can be a larger 
reservoir of asymptomatic C difficile colonization. Further efforts are also needed to explore 
other strategies for reducing transmission of C difficile from asymptomatic carriers, 
including decolonization, enhanced disinfection of the skin and environment to reduce the 
burden of spores, and decreased use of antibiotics.
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